Eulav Asset Management Continues to Hold Position in Celgene (CELG); As Array Biopharma (ARRY) Market Value Rose, Shareholder Hollencrest Securities Decreased Holding

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Hollencrest Securities Llc decreased its stake in Array Biopharma Inc (ARRY) by 29.31% based on its latest 2018Q3 regulatory filing with the SEC. Hollencrest Securities Llc sold 41,470 shares as the company’s stock rose 7.15% while stock markets declined. The institutional investor held 100,000 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $1.52M, down from 141,470 at the end of the previous reported quarter. Hollencrest Securities Llc who had been investing in Array Biopharma Inc for a number of months, seems to be less bullish one the $3.78B market cap company. The stock increased 2.66% or $0.46 during the last trading session, reaching $17.75. About 1.48 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 42.87% since January 10, 2018 and is uptrending. It has outperformed by 42.87% the S&P500. Some Historical ARRY News: 16/04/2018 – BIOTHERA PHARMACEUTICALS PRESENTS TRANSLATIONAL DATA FROM ONGOING CLINICAL TRIALS SHOWING IMPRIME PGG IN COMBINATION WITH MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DRIVES INNATE AND ADAPTIVE IMMUNE; 15/03/2018 – Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell; 03/05/2018 – European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination; 10/04/2018 – BerGenBio ASA: BerGenBio completes recruitment into first stage of Phase II NSCLC trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®; 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients With Pegzilarginase in Both Monotherapy and KEYTRUDA Combination Trials; 09/05/2018 – ARRAY BIOPHARMA INC – CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $440 MLN; 16/04/2018 – U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for; 16/04/2018 – FDA OKS BRISTOL-MYERS’ NIVOLUMAB PLUS IPILIMUMAB COMBINATION; 09/05/2018 – ARRAY BIOPHARMA 3Q REV. $66.4M, EST. $33.2M

Eulav Asset Management increased its stake in Celgene Corp (CELG) by 5.63% based on its latest 2018Q3 regulatory filing with the SEC. Eulav Asset Management bought 16,000 shares as the company’s stock declined 22.96% with the market. The institutional investor held 300,000 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $26.85 million, up from 284,000 at the end of the previous reported quarter. Eulav Asset Management who had been investing in Celgene Corp for a number of months, seems to be bullish on the $60.84 billion market cap company. The stock decreased 0.71% or $0.62 during the last trading session, reaching $86.89. About 9.94 million shares traded or 12.75% up from the average. Celgene Corporation (NASDAQ:CELG) has declined 33.15% since January 10, 2018 and is downtrending. It has underperformed by 33.15% the S&P500. Some Historical CELG News: 09/04/2018 – POLL: Which of the recent large cell/gene therapy deals will work out best for the acquirer? $NVS $AVXS $CELG $GILD; 09/04/2018 – The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene; 17/04/2018 – Celgene Corporation to Webcast at Upcoming Investor Conferences; 05/03/2018 – #3 — Celgene hands over $101M in cash to launch a research collaboration with protein player Vividion $CELG; 16/05/2018 – JOUNCE THERAPEUTICS TO PRESENT DATA FROM ONGOING ICONIC TRIAL OF JTX-2011 AT THE 2018 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING; 16/04/2018 – In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients; 18/05/2018 – U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ; 09/04/2018 – MERCK & CO INC – SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT; 21/05/2018 – EVOTEC AG EVTG.DE – UNDER TERMS OF AGREEMENT, EVOTEC WILL RECEIVE AN UPFRONT PAYMENT OF $65 MLN; 15/05/2018 – REXAHN PHARMACEUTICALS INC – SMC HAS CONFIRMED THAT COMBINATION OF RX-3117 AND ABRAXANE IS SAFE AND WELL TOLERATED

Eulav Asset Management, which manages about $2.35B and $2.33 billion US Long portfolio, decreased its stake in Salesforce Com Inc (NYSE:CRM) by 2,000 shares to 238,000 shares, valued at $37.85 million in 2018Q3, according to the filing. It also reduced its holding in British Amern Tob Plc (NYSEMKT:BTI) by 33,800 shares in the quarter, leaving it with 28,092 shares, and cut its stake in Dominos Pizza Inc (NYSE:DPZ).

Investors sentiment increased to 0.93 in 2018 Q3. Its up 0.22, from 0.71 in 2018Q2. It increased, as 58 investors sold CELG shares while 418 reduced holdings. 113 funds opened positions while 332 raised stakes. 468.90 million shares or 1.67% less from 476.86 million shares in 2018Q2 were reported. Ls Advsr Ltd Limited Liability Company holds 0.1% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 19,403 shares. Pdt Partners Limited Com has 198,074 shares. Smith & Howard Wealth Mgmt Ltd Liability Corporation holds 16,540 shares or 0.62% of its portfolio. Nordea Mgmt Ab reported 196,889 shares stake. Beech Hill Advsrs holds 2.5% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 53,975 shares. Amica Pension Fund Board Of Trustees accumulated 31,846 shares or 0.37% of the stock. Great Lakes Advsr Ltd Liability Corp has 2,883 shares for 0.01% of their portfolio. Alkeon Capital Mngmt Limited Liability Corporation holds 0.2% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 467,595 shares. 10 holds 23,962 shares. Elm Ltd Liability Corp holds 0.04% or 600 shares in its portfolio. Mairs And Pwr stated it has 2,940 shares. Riverpark Advisors Limited Liability Company reported 122,913 shares or 2.63% of all its holdings. Rathbone Brothers Public Llc holds 0.03% or 11,305 shares in its portfolio. Mraz Amerine Associates Inc has 3,400 shares. Segall Bryant Hamill Lc has invested 0.05% in Celgene Corporation (NASDAQ:CELG).

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “IVV’s Holdings Imply 25% Gain Potential – Nasdaq” on December 31, 2018, also Finance.Yahoo.com with their article: “The Daily Biotech Pulse: Aevi’s ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen – Yahoo! Finance News” published on January 03, 2019, Nasdaq.com published: “Crowded Cancer Space Triggers Big M&A Deals: More in Store? – Nasdaq” on January 08, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “Bristol-Myers to Acquire Leading Biotech Celgene for $74B – Nasdaq” published on January 04, 2019 as well as Businesswire.com‘s news article titled: “Celgene Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conference – Business Wire” with publication date: December 18, 2018.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 23 have Buy rating, 0 Sell and 12 Hold. Therefore 66% are positive. Celgene Corporation had 160 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Celgene Corporation (NASDAQ:CELG) has “Market Perform” rating given on Friday, February 5 by Leerink Swann. The firm earned “Buy” rating on Tuesday, January 23 by Canaccord Genuity. The rating was maintained by Morgan Stanley with “Equal-Weight” on Friday, July 13. The firm has “Buy” rating by Oppenheimer given on Thursday, July 6. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Canaccord Genuity on Monday, October 16. The firm has “Neutral” rating by Cantor Fitzgerald given on Friday, October 27. The firm has “Equal-Weight” rating given on Friday, July 27 by Morgan Stanley. Argus Research downgraded the stock to “Hold” rating in Friday, May 5 report. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Thursday, October 19 by RBC Capital Markets. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Cowen & Co on Tuesday, September 12.

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on February, 5. They expect $-0.16 earnings per share, up 5.88% or $0.01 from last year’s $-0.17 per share. After $-0.12 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 33.33% negative EPS growth.

Since July 18, 2018, it had 1 buy, and 6 selling transactions for $1.39 million activity. Another trade for 3,000 shares valued at $50,595 was bought by COX CARRIE SMITH. 9,687 shares were sold by Sandor Victor, worth $148,938 on Tuesday, September 4. Haddock Jason sold $278,400 worth of stock or 20,000 shares.

Among 12 analysts covering Array BioPharma (NASDAQ:ARRY), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Array BioPharma had 43 analyst reports since June 3, 2016 according to SRatingsIntel. The rating was maintained by Leerink Swann with “Outperform” on Monday, September 26. Piper Jaffray maintained Array BioPharma Inc. (NASDAQ:ARRY) on Tuesday, February 6 with “Buy” rating. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Wednesday, February 7 by Cowen & Co. As per Sunday, January 21, the company rating was maintained by Cowen & Co. Leerink Swann upgraded the shares of ARRY in report on Monday, January 22 to “Outperform” rating. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Piper Jaffray on Friday, September 8. Jefferies maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Thursday, August 24. Jefferies has “Buy” rating and $9.0 target. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Monday, August 29 by Jefferies. The firm has “Outperform” rating by Wells Fargo given on Thursday, June 28. On Tuesday, July 18 the stock rating was maintained by Cantor Fitzgerald with “Buy”.

More notable recent Array BioPharma Inc. (NASDAQ:ARRY) news were published by: Seekingalpha.com which released: “Healthcare names lead premarket gainers – Seeking Alpha” on January 07, 2019, also Fool.com with their article: “Does Eli Lilly’s $8 Billion Splurge Make Array BioPharma a Buy Now? – The Motley Fool” published on January 09, 2019, Seekingalpha.com published: “Stocks To Watch: Tech Earnings Bellwethers Set To Test Rally – Seeking Alpha” on October 20, 2018. More interesting news about Array BioPharma Inc. (NASDAQ:ARRY) were released by: Nasdaq.com and their article: “Noteworthy ETF Outflows: XBI, ACAD, IONS, ARRY – Nasdaq” published on November 16, 2018 as well as Schaeffersresearch.com‘s news article titled: “3 Drug Stocks Making Outsized Moves Today – Schaeffers Research” with publication date: January 07, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.